p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Sepharose® Bead Conjugate)Product information
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Sepharose® Bead Conjugate)
|400 µl (40 immunoprecipitations)||-||Unavailable in your region|
Product Pathways - MAPK Signaling
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Sepharose® Bead Conjugate) #5736
|5736S||400 µl (40 immunoprecipitations)||---||In Stock||---|
|5736||carrier free and custom formulation / quantity||email request|
|IP||1:20||Human, Mouse, Rat, Hamster, Monkey, Mink, D. melanogaster, Zebrafish, Bovine, Dog, Pig, C. elegans||Endogenous||42, 44||Rabbit IgG|
Species cross-reactivity is determined by western blot using the unconjugated antibody.
Applications Key: IP=Immunoprecipitation
Species predicted to react based on 100% sequence homology: Chicken.
Specificity / Sensitivity
p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Sepharose® Bead Conjugate) detects endogenous levels of total p44/42 MAPK (Erk1/2) protein. The antibody does not cross-react with JNK/SAPK or p38 MAP kinase. The addition of 0.1% SDS to the immunoprecipitation reaction may improve pulldown efficiency. Under some conditions this conjugate may immunoprecipitate p44/Erk1 preferentially over p42/Erk2.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the C-terminus of rat p44 MAP kinase.
This Cell Signaling Technology antibody is immobilized via covalent binding of primary amino groups to N-hydroxysuccinimide (NHS)-activated Sepharose® beads. p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Sepharose® Bead Conjugate) is useful for immunoprecipitation assays. The antibody is expected to exhibit the same species cross-reactivity as the unconjugated p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695.
Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.
- Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
- Baccarini, M. (2005) FEBS Lett 579, 3271-7.
- Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.
- Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
- Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
- Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
- Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
- Marais, R. et al. (1993) Cell 73, 381-93.
- Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
- Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.